AP
APGE icon

Antipodes Partners’s Apogee Therapeutics APGE Stock Holding History

Antipodes Partners’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-723
Closed -$54.6K – 129
2025
Q4 		$54.6K Sell
723
-120
-14% -$7.56K ﹤0.01% 106
2025
Q3 		$33.5K Buy
843
+246
+41% +$9.39K ﹤0.01% 104
2025
Q2 		$25.9K Buy
597
+55
+10% +$2.09K ﹤0.01% 95
2025
Q1 		$20.3K Buy
+542
New +$21K ﹤0.01% 96

Other funds holding APGE

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Antipodes Partners's APGE Position: Q1 2026 in Review

Antipodes Partners sold out of Apogee Therapeutics (APGE) in Q1 2026, closing a stake of 723 shares — an estimated $54.6K sold.

Antipodes Partners first reported a position in APGE in Q1 2025 and held it in 4 quarters. The position peaked at $54.6K in Q4 2025. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

  • Antipodes Partners reported no remaining Apogee Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Antipodes Partners sold 723 Apogee Therapeutics shares in Q1 2026, an estimated $54.6K.
  • Antipodes Partners first reported a position in Apogee Therapeutics in Q1 2025 and held it in 4 quarters.
  • Antipodes Partners's Apogee Therapeutics position peaked at $54.6K in Q4 2025.
  • 224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on Antipodes Partners's 13F filing for Q1 2026, filed 5 May 2026.